Lv11
20 积分 2024-06-14 加入
Efficacy and Safety of Immune Checkpoint Inhibition Combined with Concurrent Chemoradiotherapy in Patients with Stage III Unresectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
26分钟前
待确认
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
7小时前
已完结
FDA guideline for validation of the LAL test as an end-product endotoxin test for human and biological drugs
1天前
求助中
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges
3天前
已完结
Transforming Cold Tumors into Hot Ones with a Metal–Organic Framework-Based Biomimetic Nanosystem for Enhanced Immunotherapy
29天前
已完结
Trajectory and Functional Analysis of PD‐1high CD4+CD8+ T Cells in Hepatocellular Carcinoma by Single‐Cell Cytometry and Transcriptome Sequencing
30天前
已完结
Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti–PD-1 Immune Checkpoint Blockade
1个月前
已完结
Risk assessment and interventions for malignant ground-glass lung nodules
1个月前
已完结
AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC)
2个月前
已关闭
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)
2个月前
已关闭
皖公网安备34019202002308
